Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.57 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.57 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | CD69 | Q07108 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.46 |
| ▸ | FGF1 | P05230 | 1/20 | 0.46 |
| ▸ | FGF2 | P09038 | 1/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.46 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581221 | 1.00 | LGALS3 (0.57) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30801091 | 1.00 | LGALS3 (0.57) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL25393784 | 1.00 | LGALS3 (0.57) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL30801093 | 0.94 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL29580804 | 0.94 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL21180427 | 0.94 | LGALS3 (0.66) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL18300844 | 0.93 | LGALS3 (0.60) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL13973318 | 0.93 | LGALS3 (0.59) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL12936316 | 0.93 | LGALS3 (0.59) | LGALS3LGALS8LGALS4MAPK1CD69 | |
| SCHEMBL22193211 | 0.93 | LGALS3 (0.59) | LGALS3LGALS8LGALS4MAPK1CD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4555077-A1 | NEW FUCOSYLTRANSFERASES FOR IN VIVO SYNTHESIS OF COMPLEX FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES | DSM IP Assets B.V. (NL) | 2025-05-21 | — | — | EP | claimed |
| CN-118056901-A | Mature polypeptide sequence of synthetic oligosaccharide and application thereof | 山东恒鲁生物科技有限公司 | 2024-05-21 | — | — | CN | claimed |
| CN-118056902-A | Mature polypeptide sequence for synthesizing HMOs and application thereof | 山东恒鲁生物科技有限公司 | 2024-05-21 | — | — | CN | claimed |
| CN-118056903-A | Mature polypeptide of synthetic oligosaccharide | 山东恒鲁生物科技有限公司 | 2024-05-21 | — | — | CN | claimed |
| WO-2024013348-A1 | NEW FUCOSYLTRANSFERASES FOR IN VIVO SYNTHESIS OF COMPLEX FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES | DSM IP ASSETS B.V. (NL) | 2024-01-18 | — | — | WO | claimed |
| EP-4743476-A1 | CRYSTALLIZATION OF LACTO-N-TRIOSE II | Chr. Hansen A/S (DK) | 2026-05-20 | — | — | EP | disclosed |
| EP-4742901-A1 | METHOD TO IMPROVE A PLANT'S GROWTH, DEVELOPMENT AND RESISTANCE TO (A)BIOTIC STRESS | Globachem NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| US-12584101-B2 | Compositions and method of use for H5 competent Bifidobacterium longum subsp. Infantis | INFINANT HEALTH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12540155-B2 | Process for the purification of lacto-N-neotetraose | CHR. HANSEN A/S (DK) | 2026-02-03 | — | — | US | disclosed |
| US-20250388855-A1 | COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS | Infinant Health, Inc (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250333431-A1 | NEW CRYSTAL FORM OF TRISACCHARIDE | Shandong Henglu Biotech. Co., Ltd. (CN) | 2025-10-30 | — | — | US | disclosed |
| WO-2025083041-A1 | NEW FUCOSYLTRANSFERASES FOR IN VIVO SYNTHESIS OF COMPLEX FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES MIXTURES COMPRISING LNFP-VI OR LNFP-V | DSM IP ASSETS B.V. (NL) | 2025-04-24 | — | — | WO | disclosed |
| CN-118056901-A | Mature polypeptide sequence of synthetic oligosaccharide and application thereof | 山东恒鲁生物科技有限公司 | 2024-05-21 | — | — | CN | disclosed |
| CN-118056902-A | Mature polypeptide sequence for synthesizing HMOs and application thereof | 山东恒鲁生物科技有限公司 | 2024-05-21 | — | — | CN | disclosed |
| CN-118056903-A | Mature polypeptide of synthetic oligosaccharide | 山东恒鲁生物科技有限公司 | 2024-05-21 | — | — | CN | disclosed |
| WO-2023221758-A1 | NEW CRYSTAL FORM OF TRISACCHARIDE | 山东恒鲁生物科技有限公司 | 2023-11-23 | — | — | WO | disclosed |
| US-20220251131-A1 | PROCESS FOR THE PURIFICATION OF LACTO-N-NEOTETRAOSE | CHR. HANSEN A/S (DK) | 2022-08-11 | — | — | US | disclosed |
| WO-2022087331-A1 | A METHOD FOR MEASURING CONCENTRATION OF HUMAN MILK OLIGOSACCHARIDES (HMO) MOLECULES USING GLOCOMETER | BASF SE (DE) | 2022-04-28 | — | — | WO | disclosed |
| EP-3983422-A1 | PROCESS FOR THE PURIFICATION OF LACTO-N-NEOTETRAOSE | Chr. Hansen HMO GmbH (DE) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020249584-A9 | PROCESS FOR THE PURIFICATION OF LACTO-N-NEOTETRAOSE | Chr. Hansen HMO GmbH (DE) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584101-B2 | Compositions and method of use for H5 competent Bifidobacterium longum subsp. Infantis | FUT5, VNN1, FUT8 | LGALS3 184/4885LGALS8 34/4885LGALS4 169/4885 |
| US-20250333431-A1 | NEW CRYSTAL FORM OF TRISACCHARIDE | B3GNT2, LCT, TREH | LGALS3 120/4885LGALS8 98/4885LGALS4 150/4885 |
| US-20250388855-A1 | COMPOSITIONS AND METHOD OF USE FOR H5 COMPETENT BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS | MRPL21, VNN1, NT5M | LGALS3 2393/4885LGALS8 435/4885LGALS4 1320/4885 |
| US-12540155-B2 | Process for the purification of lacto-N-neotetraose | LCT, NANS, B3GNT2 | LGALS3 357/4885LGALS8 155/4885LGALS4 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.